Since the emergence of COVID-19 in Dec</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">...Since the emergence of COVID-19 in Dec</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> 2019, our knowledge of disease and treatment modalities has evolved significantly. Pregnancy poses a unique challenge in the context of the management of infectious diseases because of the effect of the disease and treatment modalities on the mother and fetus. There has been a lack of active inclusion of pregnant women in various trials including vaccination trials in COVID-19;hence most information on treatment strategies became available from adult non-pregnant population. This article outlines the short review on current management strategies available to the adult pregnant population with COVID-19 in light of available evidence until 30</span><sup><span style="font-family:Verdana;">th</span></sup><span style="font-family:Verdana;"> April 2021.展开更多
Since the first report of COVID-19 in December 2019, our knowledge and treatment modalities have</span><span style="font-family:""> </span><span style="font-family:Verdana;&quo...Since the first report of COVID-19 in December 2019, our knowledge and treatment modalities have</span><span style="font-family:""> </span><span style="font-family:Verdana;">evolved at great pace understanding its impact on the maternal and neonatal outcomes. Whilst pregnant patients are not more susceptible to acquiring the infection as compared to the general population, they may be at higher risk of developing severe symptoms given the physiological changes, relative immune-compromised state of pregnancy, and their neonates at risk of consequent iatrogenic preterm deliveries. Our review article discusses outcomes of pregnant women and neonates with COVID-19 from several countries including the UK, USA, France, Italy and China</span><span style="font-family:""> </span><span style="font-family:Verdana;">and provides a narrative review of literature from November 2019 till December 2020.展开更多
文摘Since the emergence of COVID-19 in Dec</span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> 2019, our knowledge of disease and treatment modalities has evolved significantly. Pregnancy poses a unique challenge in the context of the management of infectious diseases because of the effect of the disease and treatment modalities on the mother and fetus. There has been a lack of active inclusion of pregnant women in various trials including vaccination trials in COVID-19;hence most information on treatment strategies became available from adult non-pregnant population. This article outlines the short review on current management strategies available to the adult pregnant population with COVID-19 in light of available evidence until 30</span><sup><span style="font-family:Verdana;">th</span></sup><span style="font-family:Verdana;"> April 2021.
文摘Since the first report of COVID-19 in December 2019, our knowledge and treatment modalities have</span><span style="font-family:""> </span><span style="font-family:Verdana;">evolved at great pace understanding its impact on the maternal and neonatal outcomes. Whilst pregnant patients are not more susceptible to acquiring the infection as compared to the general population, they may be at higher risk of developing severe symptoms given the physiological changes, relative immune-compromised state of pregnancy, and their neonates at risk of consequent iatrogenic preterm deliveries. Our review article discusses outcomes of pregnant women and neonates with COVID-19 from several countries including the UK, USA, France, Italy and China</span><span style="font-family:""> </span><span style="font-family:Verdana;">and provides a narrative review of literature from November 2019 till December 2020.